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O B J E C T I V E   
To assess whether CC is more effective at reducing suicidal ideation in people with depression compared with usual care, and whether study and patient factors 
moderate treatment effects. 
Method: We searched Medline, Embase, PubMed, PsycINFO, CINAHL, CENTRAL from inception to March 2020 for Randomised Controlled Trials (RCTs) that 
compared the effectiveness of CC with usual care in depressed adults, and reported changes in suicidal ideation at 4 to 6 months post-randomisation. Mixed-effects 
models accounted for clustering of participants within trials and heterogeneity across trials. This study is registered with PROSPERO, CRD42020201747. 
Results: We extracted data from 28 RCTs (11,165 patients) of 83 eligible studies. We observed a small significant clinical improvement of CC on suicidal ideation, 
compared with usual care (SMD, − 0.11 [95%CI, − 0.15 to − 0.08]; I2, 0⋅47% [95%CI 0.04% to 4.90%]). CC interventions with a recognised psychological treatment 
were associated with small reductions in suicidal ideation (SMD, − 0.15 [95%CI -0.19 to − 0.11]). CC was more effective for reducing suicidal ideation among patients 
aged over 65 years (SMD, − 0.18 [95%CI -0.25 to − 0.11]). 
Conclusion: Primary care based CC with an embedded psychological intervention is the most effective CC framework for reducing suicidal ideation and older patients 
may benefit the most.   
1. Introduction 
Suicidal ideation is one of the strongest predictors of suicide, which 
is one of the leading causes of death worldwide. [1] Suicidal ideation is 
regularly measured in patient randomised trials with follow-up as 
opposed to suicide attempt and death by suicide, which are more clin-
ically relevant and devastating outcomes but also extremely rare. [2] 
Psychosocial interventions may serve as appropriate interventions for 
suicidal ideation, particularly when suicidal ideation occurs concomi-
tantly with depression. [3] Most depressed patients are treated only in 
primary care [4] and over two thirds of people successfully attempting 
suicide are in contact with their primary care physician shortly before 
death. Primary care offers an ideal setting for implementing suicide 
prevention for people with depression. [5–7] 
Collaborative care (CC) has been tested in both high, middle and low- 
income countries and it is now becoming increasingly used for the 
management of depression within primary care settings. [8,9] CC typi-
cally applies an interdisciplinary team-based care model consisting of a 
care manager, a primary care doctor and a consultant psychiatrist 
working with a patient. This follows the chronic care model, providing 
three aspects: 1) the patient has regular appointments with the nurse- 
care manager who monitors how the patient is doing and all actions 
that have to happen for treatment. In some cases, nurse care-manager 
also provides some psychotherapeutic treatment to the patient, for 
example problem solving treatment. 2) The care manager will inform 
the general practitioner about the treatment progress and if needed, the 
general practitioner will see the patient for providing antidepressant 
medication or treatment of any other chronic medical condition. 3) The 
patient can also ask the consultant psychiatrist for advice or for a 
consultation in the primary care clinic, in case of suicidal ideation or 
questions about medication or referral to the specialist mental health 
care setting. In this way, it brings specialist expertise in the domain of 
common mental disorders, most often depressive and anxiety disorders, 
within reach of care providers in the generalist primary care setting, and 
this is of crucial importance for detection and treatment of suicidal 
ideation, which is in general, a task that requires specialist knowledge. 
[10] There is ample evidence that CC is more effective for reducing 
depressive symptoms at short, medium and long-term compared to usual 
care. [8] Furthermore, multilevel interventions that include compre-
hensive and integrated approaches to care, such as CC, can be particu-
larly effective suicide prevention strategies due to their synergistic 
potential. [10] 
Two previous trials have demonstrated that CC has the potential to 
lead to reductions in suicidal ideation for people with depression. 
[11–13] However, the vast majority of CC trials for depression have not 
reported baseline or follow-up data on suicidal ideation and therefore 
the effect of CC on suicidal ideation remains mostly untested. CC is a 
complex intervention and there is significant variation in the exact na-
ture of the interventions used in different trials. A number of study-level 
factors which have already shown to influence the effects of CC for 
depressive symptoms are the inclusion of a recognised psychological 
treatment (e.g. behavioral activation, problem solving) either on its own 
or combined with medication management, recruitment of patients 
using systematic or population health approaches (e.g. disease regis-
ters), and regular clinical supervision of care managers. [14] Equally, 
patient factors may influence the effectiveness of CC for suicidal idea-
tion. Both previous trials which have shown that CC has promising ef-
fects on suicide risk but were solely based on older adults with 
depression and currently there is lack of evidence about the effects of CC 
on suicidal ideation among younger patients. Moreover, CC has been 
increasingly seen as a promising framework for integrating care for 
people with depression and comorbid chronic physical conditions rather 
than an intervention targeting depression alone. [15,16] The National 
Institute for Health and Care Excellence (NICE) guidance in the UK also 
recommends CC as treatment of choice in people with comorbid 
depressive disorders and chronic physical conditions. [9,17] 
In this study, we conducted an individual participant data (IPD) 
meta-analysis to examine whether CC is effective for reducing suicidal 
ideation among adult patients with depression at short-term follow-up 
compared with usual care. We also examined different delivery models 
of CC (i.e. intervention content, recruitment method, supervision fre-
quency of the care manager, risk of bias) and a number of subgroups of 
patients (by age, gender, and number/types of chronic physical 
conditions). 
2. Methods 
The IPD meta-analysis followed a registered (PROSPERO 
CRD201747) protocol and a statistical analysis plan. Findings are re-
ported in line with the Preferred Reporting Items for Systematic reviews 
and Meta-Analysis of Individual Participant Data (PRISMA-IPD) (eTa-
ble 1 in the supplement). [18] 
2.1. Search methods 
Bibliographic databases were searched to update the Cochrane re-
view in September 2019 (Medline, Embase, PubMed, PsycINFO, 
CINAHL, and Cochrane Central Register of Controlled Trials (CEN-
TRAL)). The search strategy is further described elsewhere [14] and the 
search and collection of eligible studies was ongoing until 30th April 
2020. The reference lists of all included trials, reviews [19] and trial 
registers (ClinicalTrials.gov, ISCTRN) were searched to identify any 
unpublished and/or important ongoing trials. Authors of all included 
studies and experts in the field were asked to identify additional pub-
lished studies and trials in progress. 
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2.2. Eligibility criteria 
Studies were selected for inclusion in the IPD analysis if they were:  
• RCTs or cluster RCTs testing collaborative care (multi-professional 
approach to patient care, structured management plan, scheduled 
patient follow-ups, and enhanced inter-professional communication) 
in comparison with usual care or enhanced usual care;  
• based on adults (age above 17 years) with depression or mixed 
anxiety and depressive disorder; and  
• reported depression scales that included one-item scores for suicidal 
ideation outcomes four to six months after randomisation. 
Studies involving adolescents and children were excluded due to 
differences in the remit of mental health services and depression man-
agement interventions provided to children, adolescents and adults. 
[20] 
2.3. Measuring suicidal ideation and chronic physical conditions 
Suicidal ideation was assessed using continuous one-item scores 
extracted from the following continuous validated scales of depression: 
item nine of the Patient Health Questionnaire 9 (PHQ9) (10 studies), 
[21] item three of the Hamilton Depression Rating (HAMD) (3 studies), 
[22] item nine of the Beck Depression Inventory (BDI) (5 studies), [23] 
item 20 of the Depression Symptom Checklist 90 (SCL-90) (2 studies), 
[24] item 13 from the Depression Symptom Checklist 20 (SCL-20) (5 
studies), item 10 from the Montgomery and Asberg Depression Rating 
Scale (MADRS) (2 studies), [25] and item nine from the Revised Clinical 
Interview Schedule for Depression (CIS-D) [26] (1 study). We focused on 
short-term suicide ideation items (extracted from depression scales) 
reported between 4 and 6 months after randomisation as most studies 
reported data availability for short-term follow-ups. 
The presence and number of chronic physical conditions were 
assessed using validated comorbidity indices such as the Charlson Co-
morbidity Index, or empirical lists of chronic physical conditions. 
Eighteen comparisons (58%) identified the types of physical conditions 
and these enabled us to classify participants as having 1 out of 5 con-
ditions: type 2 diabetes (15 comparisons), cancer (8 comparisons), 
cardiovascular disease (15 comparisons), hypertension (10 compari-
sons), and respiratory disease (11 comparisons). 
2.4. Data analysis 
Study authors were contacted to obtain primary individual-patient 
data sets for the following variables: treatment group, age, gender, 
baseline and follow-up suicidal ideation assessment scores, and number 
and types of physical chronic conditions. Information on populations, 
interventions, risk of bias, and outcome effect sizes were extracted from 
published reports using a standardised data extraction form by two in-
dependent reviewers (CG, MP). IPD data were cleaned, quality checked 
and amalgamated into a single data set. Initial separate analyses on 
depression outcomes were conducted for each study to ensure that an-
alyses were consistent with those reported in the original studies. The 
full list and codes of variables requested from all IPD collaborators are 
reported in eTable 2 in the supplement. 
Multiple imputation techniques were used to obtain more complete 
individual study datasets and to protect against bias due to data missing 
at random (MAR), missing completely at random (MCAR) or missing not 
at random (MNAR). In all three cases, multiple imputation is a method of 
addressing this bias. [27] Missing values for suicidal ideation scores at 
follow-up and age were imputed with a single multivariate normal 
imputation algorithm across 1000 datasets (mi impute mvn in Stata, v15; 
StataCorp) using Markov Chain Monte Carlo. [28,29] Each complete 
dataset was then combined according to Rubin’s rules and analysed. 
[30] The imputation model regressed age (incomplete predictor), 
suicidal ideation (incomplete outcome), treatment group, baseline sui-
cidal ideation score, gender (complete predictors) and a study identifi-
cation variable to account for clustering within studies. Including the 
outcome in the imputation model is essential, although imputing the 
outcome does not confer significant analytical benefits. [27] We esti-
mated the imputed values conditional on the observed values of the 
variables of interest. 
Two independent reviewers assessed the quality of the randomised 
controlled trials using the Cochrane risk of bias tool. Additional quality 
checks involved baseline imbalance and missing data. One-stage IPD 
meta-analysis is known to be less susceptible to bias, more efficient in 
terms of power [31] and allows for advanced modelling of covariates 
(treatment-covariate interactions). [32–34] Our outcome was suicidal 
ideation, assessed at baseline and at 4 or 6 month follow-up post-ran-
domisation, and we applied one-stage meta-analysis with mixed-effects 
models including fixed study-specific intercepts, random treatment ef-
fect, fixed study specific effects for baseline suicide ideation, fixed ef-
fects for age, gender and moderators. The analysis allowed us to separate 
out the within-study and across-study interactions (accounting for 
clustering) and avoid ecological biases by centring of the key covariates 
(age, gender). Suicidal ideation scores were standardised within each 
study, using study-specific means of the follow-up scores and the stan-
dard deviation of the baseline score. Two sensitivity analyses were 
performed to evaluate the consistency of the findings across i) imputed 
and non-imputed approaches (complete case analysis) and ii) measures 
of suicidal ideation (only retaining the most common measure - the 
ninth item of the PHQ9- in the analyses). 
We conducted pre-specified primary ‘subgroup’ analyses to examine 
whether study-level and patient-level factors moderated the effects of 
CC on suicidal ideation. Study-level moderators included (each as bi-
nary): intervention content (medication management only; psychologi-
cal/both), supervision frequency of the care manager (regular such as 
weekly supervision versus no regular supervision, recruitment method 
of participants (systematic identification of versus referred by clinician) 
and risk of bias. Allocation concealment was selected as an indicator of 
risk of bias, as it is sensitive to changes in the treatment effect, especially 
for self-reported outcomes. [35–37] Patient-level moderators included: 
age (categorical variable: 17 to 25 years age group; 26 to 65 years age 
group; and older than 65 age group), gender (binary variable), number 
of chronic physical conditions (continuous variable), and types of 
chronic physical conditions (each as a binary: diabetes, cancer, cardio-
vascular disease, hypertension, and respiratory disease). 
Control for cluster-allocated RCTs in the model was achieved by 
adherence to the methodological recommendations of Sutton. [38] 
Stata’s (v16.1) mixed and ipdforest [39,40] commands were used to pool 
evidence from studies and to obtain forest plots, respectively. Restricted 
maximum likelihood was used for model estimation. Heterogeneity was 
assessed with a one-stage meta-analysis variant of the I2 statistic and the 
estimated inter-study variance (τ2). [41] If studies included multiple 
treatment groups and a single control group, the treatment groups were 
treated as separate comparisons in the analyses, whereas the control 
groups were halved at random to avoid double counting in the analyses. 
In accord with published guidelines, [42] if more than 10 studies were 
available, we would use contour-enhanced funnel plots to assess publi-
cation bias alongside visual examination and statistical tests for asym-
metry (Egger’s test for continuous outcomes). 
3. Results 
As shown in the PRISMA IPD flowchart (Fig. 1), IPD were collected 
from 28 trials (31 comparisons), which included 11,688 participants 
corresponding to 41% of participants from eligible trials. A total of 
11,165 unique cases for the primary outcome were analysed, of which 
2125 (19.03%) were missing at follow-up and were imputed using 
multiple imputations. 
Most participants in the IPD were women (8058 [68.9%]) and the 
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mean (SD) age was 54.5 (SD = 16.6) years (range, 17–95 years). As 
many as 8204 [70.2%] participants had at least one physical condition 
and up to 20 conditions with a median of 2.5 conditions (IQR: 1 to 4 
conditions). Table 1 presents the baseline characteristics of patients 
included in the IPD by intervention arm. Thirteen studies (46.5%) in the 
IPD were conducted in the United States, [43–55] thirteen (46.5%) in 
Europe, [56–68] one (3.5%) in Canada, [69] and one (3.5%) in India. 
[70] We provide a summary table of IPD main effect and all moderator 
and sensitivity analyses in Table 2. The full descriptive characteristics of 
the included studies are presented eTable 3 and eTable 4 in the sup-
plement. Studies with IPD were compared with studies where IPD could 
not be retrieved to evaluate the outcome, population, intervention, and 
risk of bias characteristics and these comparisons are reported in eTa-
ble 5 in the supplement. The only statistically significant differences 
were for country of studies and intervention content. We were able to 
obtain data from a larger proportion of trials from countries other than 
Fig. 1. PRISMA flowchart.  
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the USA and from a larger proportion of trials with a recognised psy-
chological treatment model. 
Collaborative care was associated with a small but significant effect 
on suicidal ideation compared with usual care (SMD, − 0.13, 95% CI, 
− 0.16 to − 0.09) (Fig. 2) in the analysis with imputed values. Analysis 
without the imputed values was similar (SMD, − 0.12 [95% CI, − 0.17 to 
− 0.07]; I2 = 0.74%; 0.13% - 4.24%) with participants from all 28 RCTs 
and for this reason we report results only for those models with the 
imputed values. The sensitivity analysis including only studies that used 
the ninth item of the PHQ9 to measure suicidal ideation results were 
nearly identical (SMD, − 0.13 [95% CI, − 0.22 to − 0.03] (eFigure 3 in the 
supplement). 
The interaction term between intervention content and CC was sta-
tistically significant (interaction coefficient, − 0.14 [95%CI, − 0.24 to 
− 0.04]) whilst controlling for baseline suicide ideation score, age and 
gender, indicating that intervention content influences the treatment 
effect. More specifically, CC interventions which included a recognised 
psychological treatment model were associated with small significant 
reductions in suicidal ideation (SMD, − 0.15 [95%CI, − 0.19 to − 0.11]) 
whereas CC interventions which only included medication management 
plans did not show statistically significant reduction of suicidal ideation 
(SMD, − 0.01 [− 0.10 to 0.08]) (eFigure 1 in the supplement). 
For age, our reference group were people aged 26 to 65 years, as 
rates of suicide and attempted suicide are higher in adolescents and in 
the elderly, when compared to the middle age group. [71] The inter-
action term between age and CC was statistically significant for the 
elderly aged 66 to 95 (interaction coefficient, − 0.10 [95% CI -0.18 to 
− 0.01]) but non-significant for younger adults aged 17 to 25 years 
(interaction coefficient, − 0.03 [95%CI -0.15 to 0.09] controlling for the 
baseline scores of suicidal ideation, gender and number of chronic 
physical conditions. CC was mostly effective in reducing suicidal idea-
tion in older people (SMD, − 0.19 [95% CI, − 0.25 to − 0.12]) followed by 
younger adults 17 to 25 years (SMD, − 0.18 [95% CI, − 0.34 to − 0.02]) 
(although the confidence intervals varied widely in this group indicating 
non-significance) and people aged between 26 and 65 (SMD, − 0.09 
[95%CI, − 0.14 to − 0.05]) (eFigure 2 in the supplement). 
The interaction between the number of chronic physical conditions 
and CC was not statistically significant (interaction coefficient, − 0.01 
[95% CI, − 0.03 to 0.01]) (eFigure 4 in the supplement) indicating that 
the effects of CC are equivalent for people with LTCs and without LTCs. 
The interaction terms between individual type of chronic physical 
conditions and CC were all non-significant: cancer (interaction coeffi-
cient, − 0.04 [95%CI, − 0.24 to 0.16]), cardiac disease (interaction co-
efficient, − 0.01 [95% CI,− 0.09 to 0.09]), diabetes (interaction 
coefficient,− 0.01 [95% CI,− 0.11 to 0.09]), hypertension (interaction 
coefficient,− 0.02 [95%CI,− 0.13 to 0.09]), and respiratory disease 
(interaction coefficient, − 0.05 [95% CI, − 0.17 to 0.08]) (eFigures 5–9 in 
the supplement). 
The interaction effect between gender and the treatment effect was 
non-significant (interaction coefficient, − 0.06 [95%CI − 0.13 to 0.02]) 
(eFigure 10 in the supplement) controlling for the baseline scores of 
suicidal ideation and age. CC was associated with small significant re-
ductions in suicidal ideation for men (SMD, − 0.17 [− 0.23 to − 0.10] and 
women (SMD, − 0.11 [− 0.15 to − 0.06]). The pooled effect of CC was not 
moderated by supervision frequency (interaction coefficient, − 0.01 
[95%CI, − 0.08 to 0.06]); eFigure 11 in the supplement), recruitment 
method (interaction coefficient for systematic identification, − 0.05 
[95%CI, − 0.22 to 0.11]; interaction coefficient for referral, − 0.10 [95% 
CI, − 0.28 to 0.01;] eFigure 9 in the supplement) and risk of bias 
(interaction coefficient, 0.05 [95%CI, − 0.02 to 0.13]; eFigure 10 in the 
supplement). 
No visual or statistical evidence (Egger’s test P = 0.86) of small study 
effects was found in the contour-enhanced funnel plot (eFigure 12 in the 
supplement). 
Table 1 
Baseline characteristics of participants by intervention arm.  
Participant characteristics Collaborative care n =
6223 (53.2) 
Usual care n =
5465 (46.8) 
Gender 
Men, n (%) 1926 (31) 1703 (31.2) 
Women, n (%) 4297 (69) 3761 (68.8)  
Age 
Mean age (SD) 54.9 (16.6) 53.5 (16.7) 
17–25 years, n (%) 316 (5.3) 261 (5) 
26–65 years, n (%) 3912 (65.6) 3312 (63.6) 
≥ 65 years, n (%) 1732 (29.1) 1632 (31.4) 
Suicidal ideation, mean (SD) 1.03(3.32) 1.01 (3.08)  
Chronic physical conditions 
Mean chronic physical 
conditions (SD) 
2.49 (2.33) 2.57 (2.22) 
Any chronic physical 
condition, n (%) 
4293 (81.4) 3911 (82.4) 
Cardiovascular disease, n (%) 1418 (38.7) 1421 (40.4) 
Type 2 Diabetes, n (%) 1111 (29.2) 1095 (30) 
Cancer, n (%) 220 (8) 210 (8.1) 
Hypertension, n (%) 1215 (44.5) 1224 (46.4) 
Respiratory disease, n (%) 687 (20.7) 657 (20.6) 
Suicidal ideation standardised score range, 0 to 4, with high scores indicating 
greater suicidal ideation. 
Table 2 
Summary table of IPD main effect and all sensitivity analyses.   
Effect (SMD) 





Main effect − 0.13, 95% CI 
-0.16 to − 0.09 
28 0.74, 95% CI 0.13 to 
4.24 
Effect of patient level moderators 
Age 
17–30 years, n (%) -0.13, 95% CI 
-0.24 to − 0.02 
21 0.65, 95% CI 0.09 to 
4.67 
31–65 years, n (%) − 0.09, 95%CI 
-0.14 to − 0.05 
27 
≥65 years, n (%) − 0.19, 95% CI 
-0.25 to − 0.12 
27  
Gender 
Male − 0.15, 95% CI 
-0.23 to − 0.08 
28 0.69, 95% CI 0.11 to 
4.34 
Female − 0.10, 95% CI 
-0.16 to − 0.05 
28 
Presence of chronic 
physical conditions at 
− 0.14, 95% CI 
-0.18 to − 0.09 
24 0.64, 95% CI 0.09 to 
4.19 
Number of chronic 
physical conditions 
− 0.01, 95% CI 
-0.03 to 0.01 




− 0.15, 95% CI 
-0.23 to − 0.08 
18 – 
Type 2 diabetes, n (%) − 0.16, 95% CI 
-0.24 to − 0.07 
19 – 
Cancer, n (%) − 0.21, 95% CI 
-0.40 to − 0.02 
11 – 
Hypertension, n (%) − 0.16, 95% CI 
-0.25 to − 0.08 
13 – 
Respiratory disease, n 
(%) 
− 0.19, 95% CI 
-0.30 to − 0.08 
14 –  
Effect of study level moderators 
Intervention content 
Medication only − 0.01, 95% CI 
-0.10 to 0.08 
4 – 
Psychological or mixed − 0.15, 95% CI 
-0.19 to − 0.11 
24 – 
Allocation concealment 
(High risk of bias) 
− 0.10, 95% CI 




− 0.13, 95% CI 
-0.19 to − 0.08 
13 – 
Recruitment method 
Referral − 0.07, 95% CI 
-0.23 to − 0.09 
3 – 
Systematic identification − 0.12, 95% CI 
-0.16 to − 0.08 
25 –  
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4. Discussion 
This large IPD meta-analysis showed that collaborative care is 
associated with small, significant reductions in suicidal ideation for 
patients with depression at four to six months post-intervention. 
Embedding a recognised psychological treatment within CC either on 
its own or combined with medication management was found to be an 
important factor for achieving greater reductions on suicidal ideation. 
We also identified subgroups of participants for whom CC might be 
promising for therapeutically managing suicidal ideation. In particular, 
the patients’ age successfully determined the effect of CC on suicidal 
ideation, rather than the effects of the number of chronic comorbidities. 
CC was mostly effective for reducing suicidal ideation in patients at age 
65 and older whereas younger patient groups achieved very small re-
ductions in suicidal ideation following CC. The effect of CC on suicidal 
ideation (SMD = -0.18) for those at age 65 or older was similar to the 
effect of CC on depression found in a previous IPD meta-analysis (SMD 
= -0.22) [72] and was equal to a drop of approximately 2 points on the 
PHQ–9 scale above the change in the controls. Our findings suggest CC is 
a promising framework for reducing suicidal ideation among older 
depressed primary care patients, especially when this framework is 
incorporated with psychological interventions. 
The main strengths of this study include the large sample and the 
advanced IPD methodology which enabled us to analyse data from 
multiple studies and across several thousands of patients which have not 
been previously reported in published trials or aggregate data meta- 
analyses. The use of aggregate data meta-analysis would not be a 
viable option in this case because the published reports of CC trials do 
not report suicidal ideation outcomes. The IPD meta-analyses in 
conjunction with the use of multiple mixed-effects regression models, 
ANCOVA to adjust for baseline effect of the primary outcome, and the 
careful control for covariates allowed us to minimise biases that are 
usually found in aggregate data meta-analyses. 
However, our study also has limitations. First, IPD meta-analysis is 
susceptible to important sources of bias, such as publication, study or 
reviewer selection, and data availability bias. To address these possible 
sources of bias, we plotted funnel plots and conducted formal tests, 
which showed that publication bias was not present in the final dataset. 
We minimised study selection bias by performing rigorous searches 
across multiple electronic bibliographic databases, contacting authors 
and using a strict pre-specification of trial eligibility criteria. This 
methodology allowed us to access data from approximately 39% of all 
available data included in the 83 published RCTs of collaborative care 
for depression. Although this is below the recommended recruitment 
target (80% of data requested), most IPD meta-analyses are only able to 
obtain 25% to 34% of the available data. [73] Another limitation of this 
study is that the main outcome (suicidal ideation) was measured using 
one item scores from different depression scales. Although we stand-
ardised the effects and sensitivity analysis showed no impact on the 
overall effect, future studies are needed to apply more comprehensive 
and validated measures of suicidal ideation to allow changes in suicide 
ideation to be better evaluated in clinical terms for informing policy. 
Finally, other potential factors, such as intensity of psychological 
intervention and care manager contacts which may moderate the effects 
of CC on suicidal ideation, are poorly reported in trials and we were 
therefore unable to evaluate their effects on our suicidal ideation. 
Fig. 2. Main effect of collaborative care interventions on suicidal ideation.  
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The literature on the efficacy of collaborative care in reducing sui-
cidal ideation is limited. One large systematic review has concluded that 
suicide prevention strategies in primary care, such as screening pro-
grammes, are not particularly effective whereas evidence on the effi-
ciency of physician training programmes or care management/CC is 
limited. [74] Conclusions or recommendations about the use of primary 
care suicide prevention programmes could not be supported by the 
available evidence [74] but the authors emphasised the importance of 
pharmacological and psychological treatment of depression as a suicide 
prevention strategy. Another systematic review, which examined sui-
cide interventions in primary care, concluded that CC is effective at 
reducing suicide rates in primary care patients while there is very little 
evidence that alternative approaches such as practitioner education and 
screening for suicide risk are effective. [75] 
Our IPD meta-analysis addressed this important research gap and the 
findings are in line with the direct evidence derived from the three 
pivotal clinical trials (PROSPECT, IMPACT and INDI) found that CC 
could be a useful strategy for reducing suicidal ideation, especially for 
the older adults. [11–13] Our results indicate that CC interventions that 
include psychological therapy improve suicidal ideation more than CC 
interventions without psychological treatment. Nevertheless, the effects 
of CC are equivalent for people with LTCs and without LTCs. These 
findings agree with previous evidence on the effectiveness of CC in-
terventions for depressed patients and suggest that improvements in 
depression scores may be the main driver of reductions in suicidal 
ideation scores. Even though the effects of CC on suicidal ideation were 
smaller compared to the effects of CC on depression, evidence suggests 
that depressed patients with suicidal ideation may continue experi-
encing suicidal ideation even when the other depressed symptoms are in 
remission. [76–78] 
The main message of this study is that CC can be a potentially viable 
and effective framework for managing suicidal ideation in primary care 
settings. To be effective, such programs should include an evidence- 
based psychological intervention and they are likely to be most effec-
tive for older adults who are at the highest risk for completed suicide. 
One key advantage of CC is a strong focus on the systematic measure-
ment and management of physical and mental health conditions which 
can be a useful tool to improve suicidal ideation for older people. 
Considering that suicidal ideation can be persistent and strongly pre-
dictive of future episodes of self-harm or deaths by suicide, prospective 
suicide prevention strategies which integrate CC in primary care are 
highly encouraged by our findings. This study is the first attempt to 
synthesise findings of the effectiveness of CC on suicide ideation and 
shows that CC is effective in reducing suicide ideation at short-term 
follow-ups. Future studies may be able to discern long-term effects of 
CC on suicide ideation. 
This IPD meta-analysis is the largest and most rigorous assessment to 
date that shows CC could effectively reduce suicidal ideation in adults 
with depression. Our findings support the large-scale implementation of 
CC programs and commissioning larger CC trials (with embedded psy-
chological interventions) to reduce suicidal ideation among older adults. 
Additional research to refine such programs for younger adults at risk for 
suicide is also warrant. 
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